• Home
  • Study Details

BCG Strain Comparison

This study will evaluate differences and effectiveness of two treatments on bladder cancer. Patients with newly diagnosed High Grade Non Muscle Invasive Bladder cancer who meet qualifications will be treated with standard BCG treatment or with Tokyo-172 BCG.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female


North Carolina (Statewide)
In-person visits : 20
Total length of participation : 60 months

Looking for Specific Volunteers

Able to participate:

  • Must have confirmed high grade non muscle invasive bladder cancer
  • All visible bladder tumors removed within 30 days prior to registration in study

Not eligible if:

  • Cannot have any renal or ureter cancer involvement
  • Cannot have had prior treatment with BCG

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Matthew Nielsen
Urology - Clinic

Study Topics

Cancer (Bladder)

IRB Number


logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.